AMHR2
AMHR2, also known as MISR2 or MISRII, is the type 2 serine/threonine kinase receptor for anti-Mullerian hormone (AMH). Ligand binding assembles a receptor complex that signals through SMAD transcriptional regulators and, together with testosterone, directs male sex differentiation. Browse Assay Genie's current range of AMHR2 research reagents below, or read on for the biology behind the target.
AMHR2 is the receptor for anti-Mullerian hormone. On ligand binding, it forms a receptor complex consisting of two type II and two type I transmembrane serine/threonine kinases. The type II receptors phosphorylate and activate the type I receptors, which autophosphorylate and then bind and activate SMAD transcriptional regulators. This is the canonical signalling route of the TGF-beta receptor subfamily, and it defines how AMH converts hormone binding into a transcriptional response.
The AMHR2 gene encodes a membrane protein that belongs to the protein kinase superfamily, the TKL Ser/Thr protein kinase family and the TGFB receptor subfamily. HGNC places it in the group of type 2 receptor serine/threonine kinases, and it carries the enzyme classification EC 2.7.11.30. Alternatively spliced transcript variants encoding different isoforms have been identified. Orthologous genes are named Amhr2 in both mouse and rat, which supports work on the AMHR2 protein in rodent models.
In male development, AMH and testosterone are produced in the testes by different cells and have different effects. Testosterone promotes the development of male genitalia, while binding of AMH to AMHR2 prevents the Mullerian ducts from developing into the uterus and Fallopian tubes. Mutations in the AMHR2 gene are associated with persistent Mullerian duct syndrome type II. The receptor has also been catalogued as anti-Mullerian hormone receptor type II, the previous HGNC name, which explains the MISRII alias.
AMHR2 mediates AMH action that, with testosterone, drives male sex differentiation by preventing Mullerian duct development into the uterus and Fallopian tubes.
Mutations in the AMHR2 gene are associated with persistent Mullerian duct syndrome type II, making the receptor central to studies of this condition.
As a type 2 receptor kinase, AMHR2 activates type I receptors and SMAD regulators, offering a model for receptor complex assembly.
AMHR2 belongs to the TKL Ser/Thr kinase family and the TGFB receptor subfamily, supporting studies of transmembrane serine/threonine kinase activity.
AMHR2 is the receptor for anti-Mullerian hormone. On ligand binding it forms a complex of two type II and two type I serine/threonine kinases. Type II receptors activate type I receptors, which then activate SMAD transcriptional regulators. In males this signalling prevents Mullerian duct development into the uterus and Fallopian tubes.
AMHR2 is also called MISR2 and MISRII, and was previously named anti-Mullerian hormone receptor type II. UniProt lists the protein as anti-Muellerian hormone type-2 receptor. Alternatively spliced transcript variants encoding different isoforms have been identified, so check the datasheet of any product for its validated reactivity.
Mutations in the AMHR2 gene are associated with persistent Mullerian duct syndrome type II. Orthologues named Amhr2 exist in mouse and rat. Check the datasheet of any product for its validated reactivity before using it with a particular species.
Ligand, type I receptor and SMAD pathway partners related to AMHR2 signalling, where Assay Genie has pages.
Gene and protein annotations from HGNC, NCBI Gene and UniProt Q16671; product specifications from Assay Genie datasheets.